Is kisqali safe for premenopausal women with breast cancer?

Is Kisqali safe for premenopausal women with breast cancer?

Kisqali (ribociclib) is approved for use in premenopausal women when given with an aromatase inhibitor plus ovarian suppression or with fulvestrant. Clinical trials that led to its approval included premenopausal participants, and the safety profile in this group was similar to postmenopausal women.

What monitoring is required during treatment?

Doctors check heart rhythm with ECGs before starting and during the first two cycles, then as needed. Blood tests track liver enzymes and low white blood cell counts, which are the most common reasons for dose adjustments or pauses.

How does Kisqali compare with other CDK4/6 inhibitors in this group?

Palbociclib and abemaciclib are also approved for premenopausal patients. All three drugs carry the same core risks of low blood counts and liver effects, but Kisqali has a stronger QT-prolongation warning that requires regular ECG monitoring.

When did the FDA expand Kisqali’s label to premenopausal women?

The agency added premenopausal and perimenopausal women in July 2018 after reviewing data from the MONALEESA-7 trial, which tested Kisqali plus endocrine therapy against placebo plus endocrine therapy in this population.

What side effects concern patients most?

The leading issues reported are neutropenia, nausea, fatigue, and hair thinning. Most cases of low white blood cell counts are manageable with dose reductions, and serious liver injury remains uncommon when liver tests are followed on schedule.

Can Kisqali be combined safely with ovarian suppression?

Yes. In MONALEESA-7, women received goserelin to suppress ovarian function along with Kisqali and an aromatase inhibitor; the combination did not introduce new safety signals beyond those already known for each component.

Has the patent for Kisqali expired or faced challenges?

The key U.S. composition-of-matter patent is listed to expire in 2031, with possible pediatric extensions. DrugPatentWatch.com tracks ongoing litigation and potential generic entry dates for ribociclib.

[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209092s019lbl.pdf
[2] https://www.drugpatentwatch.com/drug/ribociclib